- Home
- JFR vs AKBA Comparison
JFR vs AKBA Comparison
Compare JFR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- AKBA
- Stock Information
- Founded
- JFR 2004
- AKBA 2007
- Country
- JFR United States
- AKBA United States
- Employees
- JFR N/A
- AKBA N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- AKBA Health Care
- Exchange
- JFR Nasdaq
- AKBA Nasdaq
- Market Cap
- JFR 1.1B
- AKBA 958.6M
- IPO Year
- JFR N/A
- AKBA 2014
- Fundamental
- Price
- JFR $8.53
- AKBA $3.42
- Analyst Decision
- JFR
- AKBA Strong Buy
- Analyst Count
- JFR 0
- AKBA 5
- Target Price
- JFR N/A
- AKBA $6.90
- AVG Volume (30 Days)
- JFR 621.7K
- AKBA 3.7M
- Earning Date
- JFR 01-01-0001
- AKBA 08-07-2025
- Dividend Yield
- JFR 11.31%
- AKBA N/A
- EPS Growth
- JFR N/A
- AKBA N/A
- EPS
- JFR N/A
- AKBA N/A
- Revenue
- JFR N/A
- AKBA $203,733,000.00
- Revenue This Year
- JFR N/A
- AKBA $27.95
- Revenue Next Year
- JFR N/A
- AKBA $43.88
- P/E Ratio
- JFR N/A
- AKBA N/A
- Revenue Growth
- JFR N/A
- AKBA 16.75
- 52 Week Low
- JFR $7.61
- AKBA $1.07
- 52 Week High
- JFR $8.82
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- JFR 59.83
- AKBA 44.17
- Support Level
- JFR $8.47
- AKBA $2.92
- Resistance Level
- JFR $8.53
- AKBA $3.79
- Average True Range (ATR)
- JFR 0.04
- AKBA 0.20
- MACD
- JFR -0.00
- AKBA -0.06
- Stochastic Oscillator
- JFR 90.00
- AKBA 44.64
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.